![closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons](../news/img/healthcare/closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_Commons.jpg)
VIR has improved significantly its earnings in the fiscal time-frame ending September 30 2022 in proportion to similar quarter a year prior, earnings jumped by 58.54 % to $1.30 and Revenue soared by 261.486 % to $
374.56 millions.
in proportion to the previous quarter net profit per share turned positive from $-0.58 per share and Revenue turned positive from $-40.63 millions.
Net income of $175.312 millions in the July to September 30 2022 period increased by 58.76 % from net earnings of $110.428 millions reported in the July to September 30 2022 period a year ago. Vir Biotechnology Inc shifted it's focus on improving sales in the July to September 30 2022 period, as a result net margin eased to 46.81%.
Vir Biotechnology Inc is expected to report next financial earnings on February 27, 2023.